Filtered By:
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 7418 results found since Jan 2013.

Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia
This study aimed to confirm the rat findings in a higher animal model and determine whether acute high-dose vigabatrin evokes retinotoxicity symptoms seen with chronic use clinically in humans. Vigabatrin dose escalation studies were conducted 20-kg swine exposed to HBO at 132 or 165 fsw. The saline group had seizure latencies of 7 and 11 min at 165 and 132 fsw, respectively. Vigabatrin at 180 mg/kg significantly increased latency (13 and 27 min at 165 and 132 fsw, respectively); 250 mg/kg abolished seizure activity at all depths. Functional electroretinogram and histology of the retinas showed no signs of retinal toxicity...
Source: Journal of Applied Physiology - September 15, 2013 Category: Physiology Authors: Hall, A. A., Young, C., Bodo, M., Mahon, R. T. Tags: ARTICLES Source Type: research

Biofilm inhibitors targeting the outer membrane protein A of Pasteurella multocida in swine.
This study aimed to discover biofilm inhibitors against swine Pm to counteract antibiotic resistance and decrease virulence. The virulence factor outer membrane protein A (OmpA) was targeted. A library of drugs approved by the Food and Drug Administration (FDA) was used to perform virtual screening against PmOmpA. The top-scoring compounds had no effect on the growth of Pm serotype A or D. Mycophenolate mofetil showed the highest efficacy in inhibiting biofilm formation by Pm serotype A, with an IC50 of 7.3 nM. For Pm serotype D, indocyanine green showed the highest effect at an IC50 of 11.7 nM. Nevertheless, these compoun...
Source: Biofouling - November 27, 2016 Category: Molecular Biology Authors: Kubera A, Thamchaipenet A, Shoham M Tags: Biofouling Source Type: research

Next Phase of NIH Preprint Pilot Launching Soon
Last month, the National Library of Medicine (NLM)announced plans to extend its NIH Preprint Pilot in PubMed Central (PMC) and PubMed beyond COVID-19 to encompass all preprints reporting on NIH-funded research. The second phase of the pilot, launching later this month, will include preprints supported by an NIH award, contract, or intramural program and posted to aneligible preprint server on or after January 1, 2023.In preparation for the launch of this second phase, we have updated PMC and PubMed site features to help users of these databases incorporate the increased volume of preprints into their discovery workflows. S...
Source: PubMed Central News - January 10, 2023 Category: Databases & Libraries Source Type: news

Second Phase of the NIH Preprint Pilot Launched
Today, we are pleased to announce the launch of the second phase of the NIH Preprint Pilot with the addition of more than 700 new preprint records to PubMed Central (PMC) and PubMed. This second phase expands the scope of the Pilot to include preprints resulting from all NIH-funded research. Eligible preprints are those acknowledging direct support of an NIH award or authored by NIH staff and posted to bioRxiv, medRxiv, arXiv, or Research Square, on or after January 1, 2023. NLM will automatically include the full text of the preprint (as license terms allow) and associated citation information in PMC and PubMed, respectiv...
Source: PubMed Central News - January 30, 2023 Category: Databases & Libraries Source Type: news

Molecules, Vol. 28, Pages 570: Structural Analysis, Multi-Conformation Virtual Screening and Molecular Simulation to Identify Potential Inhibitors Targeting pS273R Proteases of African Swine Fever Virus
In this study, the conformation of the pS273R protease in physiological states were investigated, virtually screened the multi-protein conformation of pS273R target proteins, combined various molecular docking scoring functions, and identified five potential drugs from the Food and Drug Administration drug library that may inhibit pS273R. Subsequent validation of the dynamic interactions of pS273R with the five putative inhibitors was achieved using molecular dynamics simulations and binding free energy calculations using the molecular mechanics/Poison-Boltzmann (Generalized Born) (MM/PB(GB)SA) surface area. These findings...
Source: Molecules - January 6, 2023 Category: Chemistry Authors: Gen Lu Kang Ou Yihan Zhang Huan Zhang Shouhua Feng Zuofeng Yang Guo Sun Jinling Liu Shu Wei Shude Pan Zeliang Chen Tags: Article Source Type: research

FDA takes steps to withdraw approval of the swine drug carbadox due to safety concerns
Today, the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) took the first step toward rescinding its approval of the use of carbadox to treat swine because the drug may leave trace amounts of a carcinogenic residue.
Source: Food and Drug Administration - April 8, 2016 Category: American Health Source Type: news

Sa2064 A NOVEL SWINE ESOPHAGEAL STRICTURE MODEL CREATED VIA ESOPHAGOGASTRODUODENOSCOPY ARGON PLASMA COAGULATION PROCEDURE
Gastrointestinal luminal strictures are notoriously difficult to treat. Repeat endoscopic through the scope (TTS) dilations are oftentimes required. Intra-stricture injection of steroids have been attempted with mixed results. To date, there is no Food and Drug Administration (FDA) approved anti-fibrotic drug proven to delay stricture reformation after endoscopic dilation. In part, the lack of effective therapeutics is due to lack of appropriate animal models. Here, we report a patient-like model of luminal stricture created in swine.
Source: Gastrointestinal Endoscopy - May 31, 2020 Category: Gastroenterology Authors: Ling Li, Yue Li, Olaya I. Brewer Gutierrez, Haijie Hu, Mohamad I. Itani, George Fayad, Jean A. Donet, Vivek Kumbhari, Florin Selaru Tags: Poster abstracts Source Type: research

FDA’s CDER and CDRH Release 2015 Guidance Agenda and Comprehensive Document Search Tool
The Food and Drug Administration seems poised for a busy 2015. The Agency’s Center for Drug Evaluation and Research (CDER) just released their annual guidance document agenda for 2015. They intend to publish 90 guidance documents this year, including several aimed at advertising, biosimilars, pharmaceutical quality and manufacturing standards, and the Drug Supply Chain Security Act. The Center for Devices and Radiological Health (CDRH) released their 2015 plan as well--indicating Laboratory Developed Test and software-related guidances are in the works. To cap off a busy new year, FDA also released a well-organized guida...
Source: Policy and Medicine - January 14, 2015 Category: American Health Authors: Thomas Sullivan Source Type: blogs

Use of internet search logs to evaluate potential drug adverse events.
Abstract Internet search logs provide an abundant source of data that can be explored for purposes such as identifying drug exposure-adverse event relationships. The methodology to rigorously conduct such evaluations is not well characterized, and the utility of such analyses is not well defined. In this issue, White and colleagues propose an approach using Internet search logs for this purpose and compare it to parallel analyses conducted using the US Food and Drug Administration's spontaneous reporting database. PMID: 25056395 [PubMed - in process]
Source: Clinical Pharmacology and Therapeutics - July 28, 2014 Category: Drugs & Pharmacology Authors: Sarntivijai S, Abernethy DR Tags: Clin Pharmacol Ther Source Type: research

Director's Comments: Internet Search Provides Early Warning of Drug Interaction
Listen to the NLM Director's Comments on "Internet Search Provides Early Warning of Drug Interaction". The transcript is also available. A novel Internet search (based on six million users) discovered harmful side effects from taking two prescription medicines — prior to safety warnings from the conventional, physician-based reporting method used by the U.S Food and Drug Administration (the FDA)...
Source: What's New on MedlinePlus - May 17, 2013 Category: Consumer Health News Source Type: news

Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Abstract Since the approval of the proteasome inhibitor, Velcade(®), by the Food and Drug Administration (FDA) for the treatment of relapsed multiple myeloma, inhibitors of the ubiquitin-proteasome system have been attracting increasing attention as promising drug leads for cancer therapy. While the development of drugs for diseases related to this proteolytic system has mainly been achieved by searching libraries of synthetic small molecules or chemical modifications to drug leads, limited searches have been conducted on natural sources. We have been searching natural sources for inhibitors that target this prot...
Source: Chemical and Pharmaceutical Bulletin - February 3, 2016 Category: Drugs & Pharmacology Authors: Tsukamoto S Tags: Chem Pharm Bull (Tokyo) Source Type: research

FDA Regulates Internet Search
The Food and Drug Administration wants to regulate Internet search.
Source: Forbes.com Healthcare News - February 15, 2013 Category: Pharmaceuticals Authors: Scott Gottlieb Source Type: news

FDA Was Right To Block 23andMe
A few techno-libertarians are up in arms over the FDA’s letter warning the genetics company 23andMe to stop selling its personalized genome services kit. But a quick search of the Food and Drug Administration’s admittedly user-unfriendly website shows federal regulators have been targeting various low-cost genetic testing ventures to provide the necessary analysis that goes along with a proper genetic screening for at least the past three years.At present, getting raw data about your personal genome is worse than useless, as Nancy Shute pointed out in a Scientific American article that I edited back in 2012. &#...
Source: Scientific American - Official RSS Feed - November 25, 2013 Category: Science Tags: Health Source Type: research

Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
Abstract Abstract 1.  Recently, the Food and Drug Administration (FDA) and European Medicines Agency have shown decision trees to determine whether a drug candidate is an inhibitor of P-glycoprotein (P-gp). However, there has been no clear information on whether P-gp inhibition can be significant in clinical drug-drug interactions (DDIs). The purpose of this study was to confirm the effect of P-gp inhibition through comprehensive analysis of the clinical DDI studies. 2.   Clinical information on P-gp inhibition was collected using the University of Washington Metabolism and Transport Drug Interaction Database...
Source: Xenobiotica - June 17, 2014 Category: Research Authors: Umeyama Y, Fujioka Y, Okuda T Tags: Xenobiotica Source Type: research

Title: In Search of “Just Right”: The Challenge of Regulating Arsenic in Rice
Charles W. Schmidt, MS, an award-winning science writer from Portland, ME, has written for Discover Magazine, Science, and Nature Medicine. Background image: © Koji Kitagawa/amanaimages/Corbis About This Article open Citation: Schmidt CW. 2015. In search of “just right”: the challenge of regulating arsenic in rice. Environ Health Perspect 123:A16–A19; http://dx.doi.org/10.1289/ehp.123-A16 News Topics: Agriculture and Farming, Arsenic, Diet and Nutrition, Drinking Water Quality, Food Safety and Regulation, Laws, Regulations, and Policy, Risk Assessment, Soil Pollution, Standards Published: 1 January 2015 PDF Ver...
Source: EHP Research - December 31, 2014 Category: Environmental Health Authors: Web Admin Tags: Featured News Spheres of Influence Agriculture and Farming Arsenic Diet and Nutrition Drinking Water Quality Food Safety and Regulation Risk Assessment Soil Pollution Standards Source Type: research